Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Oncoscience|January 17, 2015
Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agentsMarie-Therese Häberle, Elena Kelsch, Karola Dorsch, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 23, 2015
Validation of a Manual Protocol for BRAF V600E Mutation-specific ImmunohistochemistryHanns C Dinges, David Capper, Olga Ritz, et al.
Cancer Research|July 20, 2007
Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphomaSergey W Popov, Gerhard Moldenhauer, Beate Wotschke, et al.
Blood|May 9, 2009
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphomaOlga Ritz, Chrystelle Guiter, Flavia Castellano, et al.
Blood|November 5, 2005
AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignanciesGerhard Moldenhauer, Sergey W Popov, Beate Wotschke, et al.
Oncotarget|January 9, 2013
SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patientsBirgit Schif, Jochen K Lennerz, Christian W Kohler, et al.
Oncotarget|July 16, 2013
STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)Olga Ritz, Karolin Rommel, Karola Dorsch, et al.
International Journal of Cancer|November 16, 2005
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 proteinIngo Melzner, Marc A Weniger, Alexandra J Bucur, et al.
Pageof 2